시장보고서

상품코드

1629226

세계의 인슐린 글라진 시장 : 유형별, 당뇨병 유형별, 유통 채널별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2024-2032년)

Insulin Glargine Market, By Type, By Diabetes Type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 12월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

인슐린 글라진 시장 역학

인슐린 글라진 시장 규모는 2023년에 18억 2,098만 달러에 달하며, 2024-2032년에 CAGR 6.50%로 확대

전 세계 당뇨병 유병률 증가로 시장 수요 증가 촉진

세계의 인슐린 글라진 시장은 전 세계에서 5억 3,700만 명의 성인이 진단받은 2형 당뇨병의 유병률 증가에 의해 주도되고 있습니다. 노인 인구 증가는 인슐린 치료에 대한 수요를 더욱 증가시킬 것입니다. 정부의 의료 구상과 바이오시밀러의 가용성은 비즈니스 기회를 창출합니다. 또한 스마트 인슐린 펜과 펌프와 같은 첨단 인슐린 전달 시스템의 개발로 보다 편리하고 정확한 인슐린 투여 방법이 제공되고 있습니다. 그러나 복잡한 제조 공정과 반도체 부족과 같은 공급망 혼란이 성장의 걸림돌로 작용하고 있습니다.

인슐린 글라진 시장 : 주요 고려사항

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 6.50%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

유형별로는 랜타스가 2023년 가장 큰 시장 점유율을 차지할 것으로 예측됩니다.

당뇨병 유형별로는 2023년 2형 당뇨병이 주요 부문을 차지할 것으로 예상됩니다.

지역별로는 2023년 북미가 주요 수입원이 되었습니다.

인슐린 글라진 시장 : 세분화 분석

세계의 인슐린 글라진 시장은 유형, 당뇨병 유형, 유통 채널, 지역에 따라 세분화됩니다.

시장은 유형별로 바사그라, 란타스, 솔리카/슬리카, 토지오, 기타로 분류됩니다. 시장을 독점하고 있는 것은 란타스입니다. 그 주요 이유는 지속형 인슐린 제제로서의 효능이 확립되어 있고, 환자와 의사의 선호도가 널리 퍼져 있기 때문입니다. 그 인기는 광범위한 임상적 사용과 강력한 브랜드 인지도에 의해 더욱 지원됩니다.

이 시장은 당뇨병 유형에 따라 1형 당뇨병과 2형 당뇨병으로 구분되며, 2형 당뇨병 부문이 시장을 지배하고 있으며, 예측 기간 중에도 우위를 유지할 것으로 예상됩니다. 이러한 성장의 원동력은 고령화, 도시화, 라이프스타일 변화 등의 요인으로 인해 전 세계에서 2형 당뇨병 유병률이 증가하고 있기 때문입니다.

인슐린 글라진 시장 : 지역별 분석

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 걸쳐 있습니다. 이 지역은 비즈니스를 가져 오는 국가별로 더 세분화됩니다.

인슐린 글라진 시장 : 경쟁 구도

인슐린 글라진 시장은 장기지속형 인슐린 제제에 대한 수요 증가로 인해 성장하고 있습니다. 기업은 환자의 순응도를 높이고 부작용을 최소화하기 위해 제품의 제형 개선에 집중하고 있습니다. 또한 경쟁 전략으로는 판매망을 확대하기 위한 제휴 및 공동 개발, 비용 효율적인 대안을 제공하기 위한 바이오시밀러 개발에 대한 투자 등이 있습니다. 일부 기업은 디지털 헬스와의 통합을 통해 종합적인 당뇨병 관리 솔루션을 제공함으로써 장기적인 사용자 참여를 목표로 하고 있습니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제11장 주요 벤더 분석 : 인슐린 글라진 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- Amigoz Lifesciences
- Biogenomics Limited
- Endocrine Technologies, Inc.
- Accurate Chemical &Scientific Corporation
- Spectrum Chemical Mfg. Corp.
- Alfa Chemical Corp.
- Sekisui Diagnostics LLC
- Biocon
- Sanofi-Aventis
- Lilly
- Novo Nordisk A/S
- Trumac Healthcare
- ADOCIA
- Gan &Lee Pharmaceuticals
- Lupin Ltd.
- WOCKHARDT
- Pfizer Inc.
- Cipla Inc.
- Loka Biosciences
- Others

제12장 AnalystView의 전방위적 분석

KSA 25.02.13

REPORT HIGHLIGHT

Insulin glargine market size was valued at USD 1,820.98 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

Insulin glargine is a long-acting basal insulin analog used to help control blood sugar levels in individuals with diabetes. Unlike rapid-acting insulins, insulin glargine provides a steady release of insulin over approximately 24 hours, minimizing peaks and reducing the risk of blood sugar fluctuations. It is typically administered once daily, offering convenience and sustained blood sugar control, and is especially beneficial for patients with type 1 or type 2 diabetes requiring consistent insulin levels.

Insulin Glargine Market- Market Dynamics

Increasing incidence of diabetes worldwide to propel market demand

The global insulin glargine market is driven by the rising prevalence of type 2 diabetes, with 537 million adults diagnosed globally. The growing elderly population further increases demand for insulin therapies. Opportunities arise from government healthcare initiatives and the availability of biosimilars. Moreover, the development of more advanced insulin delivery systems, such as smart insulin pens and pumps, offers a more convenient and precise way to administer insulin glargine. However, the complex manufacturing process and supply chain disruptions, like semiconductor shortages, hinder growth.

Insulin Glargine Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on type segmentation, lantus was predicted to show maximum market share in the year 2023

Based on diabetes type segmentation, type 2 diabetes was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Insulin Glargine Market- Segmentation Analysis:

The Global Insulin Glargine Market is segmented on the basis of Type, Diabetes Type, Distribution Channell, and Region.

The market is divided into three categories based on type: basaglar, lantus, soliqua/suliqua, toujeo, and others. The lantus sector dominates the market. This is majorly due to its established efficacy as a long-acting insulin solution and widespread patient and physician preference. Its popularity is further supported by extensive clinical usage and strong brand recognition.

The market is divided into two categories based on diabetes type: type 1 diabetes and type 2 diabetes. The type 2 sector dominates the market and is likely to maintain its dominance during the forecast period. This growth is driven by the rising prevalence of type 2 diabetes worldwide, fueled by factors such as aging populations, urbanization, and lifestyle changes.

Insulin Glargine Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Insulin Glargine Market- Competitive Landscape:

The insulin glargine market is expanding due to the rising demand for long-acting insulin solutions. Companies are focusing on improving product formulations to enhance patient compliance and minimize side effects. Additionally, competitive strategies include partnerships and collaborations to broaden distribution networks, as well as investment in biosimilar development to offer cost-effective alternatives. Some firms are also focusing on digital health integrations to provide comprehensive diabetes management solutions, targeting long-term user engagement.

Recent Developments:

In April 2024, Sanofi India announced the launch of Soliqua, a new diabetes treatment for adults with type 2 diabetes and obesity. Approved by CDSCO, it helps improve glycemic control alongside diet and exercise.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INSULIN GLARGINE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amigoz Lifesciences
Biogenomics Limited
Endocrine Technologies, Inc.
Accurate Chemical & Scientific Corporation
Spectrum Chemical Mfg. Corp.
Alfa Chemical Corp.
Sekisui Diagnostics LLC
Biocon
Sanofi-Aventis
Lilly
Novo Nordisk A/S
Trumac Healthcare
ADOCIA
Gan & Lee Pharmaceuticals
Lupin Ltd.
WOCKHARDT
Pfizer Inc.
Cipla Inc.
Loka Biosciences
Others

GLOBAL INSULIN GLARGINE MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Basaglar
Lantus
Soliqua/Suliqua
Toujeo
Others

GLOBAL INSULIN GLARGINE MARKET, BY DIABETES TYPE- MARKET ANALYSIS, 2019 - 2032

Type 1 Diabetes
Type 2 Diabetes

GLOBAL INSULIN GLARGINE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Online Pharmacies
Retail Pharmacies
Hospital Pharmacies

GLOBAL INSULIN GLARGINE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Insulin Glargine Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Insulin Glargine Market Snippet by Type
- 2.1.2. Insulin Glargine Market Snippet by Diabetes Type
- 2.1.3. Insulin Glargine Market Snippet by Distribution Channel
- 2.1.4. Insulin Glargine Market Snippet by Country
- 2.1.5. Insulin Glargine Market Snippet by Region
2.2. Competitive Insights

3. Insulin Glargine Key Market Trends

3.1. Insulin Glargine Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Insulin Glargine Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Insulin Glargine Market Opportunities
3.4. Insulin Glargine Market Future Trends

4. Insulin Glargine Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Insulin Glargine Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Insulin Glargine Market Landscape

6.1. Insulin Glargine Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Insulin Glargine Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
- 7.1.2. Basaglar
- 7.1.3. Lantus
- 7.1.4. Soliqua/Suliqua
- 7.1.5. Toujeo
- 7.1.6. Others

8. Insulin Glargine Market - By Diabetes Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Diabetes Type, 2023 & 2032 (%)
- 8.1.2. Type 1 Diabetes
- 8.1.3. Type 2 Diabetes

9. Insulin Glargine Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
- 9.1.2. Online Pharmacies
- 9.1.3. Retail Pharmacies
- 9.1.4. Hospital Pharmacies

10. Insulin Glargine Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Insulin Glargine Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Insulin Glargine Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. Italy
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. Italy Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. United Kingdom
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. United Kingdom Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. France
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. France Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Russia
  - 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.3. Russia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. Netherlands
  - 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.3. Netherlands Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Poland
  - 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.3. Poland Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Rest of Europe
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Rest of the Europe Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Insulin Glargine Key Manufacturers in Asia Pacific
- 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. Asia Pacific Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. India
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. India Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. China
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. China Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Thailand
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Thailand Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Indonesia
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Indonesia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America
- 10.5.1. Overview
- 10.5.2. Insulin Glargine Key Manufacturers in Latin America
- 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. Latin America Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa
- 10.6.1. Overview
- 10.6.2. Insulin Glargine Key Manufacturers in Middle East and Africa
- 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. Middle East and Africa Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
- 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. United Arab Emirates
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. United Arab Emirates Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Diabetes Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Insulin Glargine Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Amigoz Lifesciences
- 11.2.2. Biogenomics Limited
- 11.2.3. Endocrine Technologies, Inc.
- 11.2.4. Accurate Chemical & Scientific Corporation
- 11.2.5. Spectrum Chemical Mfg. Corp.
- 11.2.6. Alfa Chemical Corp.
- 11.2.7. Sekisui Diagnostics LLC
- 11.2.8. Biocon
- 11.2.9. Sanofi-Aventis
- 11.2.10. Lilly
- 11.2.11. Novo Nordisk A/S
- 11.2.12. Trumac Healthcare
- 11.2.13. ADOCIA
- 11.2.14. Gan & Lee Pharmaceuticals
- 11.2.15. Lupin Ltd.
- 11.2.16. WOCKHARDT
- 11.2.17. Pfizer Inc.
- 11.2.18. Cipla Inc.
- 11.2.19. Loka Biosciences
- 11.2.20. Others

12. 360 Degree Analyst View

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us